Navigation Links
Chiltern Announces The Consolidation Of Existing Investor Base
Date:12/17/2013

LONDON and WILMINGTON, N.C., Dec. 17, 2013 /PRNewswire/ -- Chiltern International Limited ("Chiltern" or "the Company"), a global contract research organization (CRO), announces the consolidation of the ownership of existing investors, led by interests associated with Sir Douglas Myers. This consolidated investor base enables Chiltern to continue to deliver on its strategic plan for growth while maintaining its focus on the delivery of high quality, innovative clinical trial services and therapeutic expertise.

The new ownership structure offers greater access to new investment to further the development of Chiltern. It will provide Chiltern with the means to expand further and develop within key target markets, both organically and through investment in people, technology and client relationships, as well as external opportunities to optimize Chiltern's mid-tier leadership position through carefully targeted acquisitions.

Demand for Chiltern's services is at an all-time high: the Company announced a record financial performance in the year ended March 2013, with top line growth of 16.8% to £104m, taking the five year revenue CAGR to 15.3% for 2008-2013. The new investment will allow Chiltern to maintain this substantial growth and to continue to drive the Company forward.

The global CRO market is expected to show continued growth as the pharmaceutical industry responds to significant sector challenges. These include the growing pressure to increase R&D productivity, the rising cost and complexity of clinical trials, increasing regulatory hurdles, and a desire to shift fixed to variable cost. These industry drivers represent a significant opportunity for Chiltern.

Nick Thornton, Chairman of Chiltern, said: "This new investment is a significant milestone in Chiltern's history. For over 30 years, Chiltern's success has been underpinned by a tradition of ownership led by private investment. We have continued to grow our market share as our customers have increasingly sought mid-tier global CROs with the ability to deliver better value and a comprehensive range of high quality services."

Jim Esinhart, CEO of Chiltern, said: "This investment will allow us to continue to invest in organic growth and explore external acquisition opportunities. I am excited to be leading Chiltern to the next phase of growth. Our mission has not changed – we are committed and will continue to deliver expert, high quality, clinical development services around the world whilst building trustworthy and lasting relationships, understanding each customer's specific needs and, overall, improving the quality of life."

Company profile:About Chiltern:
Established in 1982, Chiltern is a leading global clinical CRO with extensive experience in the management of Phase I-IV clinical trials across a broad range of therapeutic areas, functional service provision and contract staffing solutions. Chiltern has conducted trials in more than 40 countries, employs more than 1,600 people globally and offers services in Early Phase, Global Clinical Development, Late Phase, Biometrics, Medical and Regulatory Affairs and Resourcing Solutions. Chiltern prides itself as a development partner that offers flexibility, responsiveness and quality delivery. For further information: www.chiltern.com. For more information contact: Natalie ChongSusan OjanenMarketing DirectorMarketing ExecutiveChiltern International Ltd.Chiltern International Inc.171 Bath Road1241 Volunteer ParkwaySloughSuite 950Berkshire SL1 4AABristol, TN 37620UNITED KINGDOMUSATel:  +44 (0) 1753 512Tel:  +1 (423) 968 9533Email: natalie.chong@chiltern.comEmail: susan.ojanen@chiltern.comFor financial enquiries contact: John DineenBen AtwellSenior DirectorSenior Managing DirectorFTI Consulting FTI ConsultingHolborn GateHolborn Gate 26 Southampton Buildings26 Southampton BuildingsLondon WC2A 1PBLondon WC2A 1PBUNITED KINGDOMUNITED KINGDOMTel: +44 (0) 20 7269 7193 directTel: +44 (0) 20 7269 7242 directFax: +44 (0) 203 077 0519Fax: +44 (0) 203 077 0519 Email: John.Dineen@fticonsulting.comEmail: Ben.Atwell@fticonsulting.com


'/>"/>
SOURCE Chiltern
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Cynosure Announces Successful Settlement of Patent Infringement Lawsuits Against Tria Beauty
2. Zimmer Announces Fourth Quarter Dividend and New Share Repurchase Program
3. Varian Imaging Components President Robert Kluge Announces Plans to Retire; Varian CEO Dow Wilson Names Sunny Sanyal as Kluges Successor
4. Medical Tracking Solutions, Inc. announces new client Custom Spine, Inc.
5. Avista Capital Partners Announces a Majority Investment in Vertical Pharmaceuticals and Trigen Laboratories
6. BioLineRx Announces Promising Initial Phase 2 Results of Acute Myeloid Leukemia Treatment
7. Amgen Announces 2014 First Quarter Dividend
8. BioSpecifics Technologies Corp. Announces Initiation of Phase 2b Trial of CCH for Treatment of Frozen Shoulder Syndrome
9. Ventana announces HER2 companion diagnostic to identify breast cancer patients for Roches latest targeted medicines, Perjeta and Kadcyla
10. Celsion Corporation Announces Combined Clinical Data from Two Phase I Trials at the 2013 San Antonio Breast Cancer Conference
11. Auxilium Pharmaceuticals, Inc. Announces First Patient Dosed in Phase 2b Frozen Shoulder Syndrome Study of Collagenase Clostridium Histolyticum
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/12/2019)... (PRWEB) , ... August 12, 2019 , ... Intalere, the ... has been named as a finalist in the Innovator of The Year - Health ... are honored to be recognized by the Pittsburgh Technology Center as a healthcare IT ...
(Date:8/10/2019)... ... August 10, 2019 , ... ... outpatient programs. Educating parents to obtain mental health screenings for early onset of ... shootings and provided a solution to the community with free assessment reviews. At ...
(Date:8/9/2019)... ANGELES (PRWEB) , ... August 09, 2019 , ... ... an exclusive interview with Anpac Bio CEO Dr. Chris Yu to discuss their ... an up-and-coming international cancer screening company that has developed a novel technology based ...
Breaking Medicine Technology:
(Date:8/14/2019)... N.H. (PRWEB) , ... August 13, 2019 , ... New ... the heart-healthy antioxidant resveratrol, today announced an expansion of its line of CBD-infused coffees ... 300 mg of CBD in a 12-oz bag. , “We are excited to ...
(Date:8/14/2019)... ... ... In a recent Trivedi Effect workshop, Master Dahryn Trivedi spoke about the path ... obliterate your old beliefs,” said Master Dahryn. “Doubt helps you look at your belief ... your awareness. Trust that the Divine has put you here for a purpose.” ...
(Date:8/14/2019)... ... ... While it is commonly understood that good nutrition promotes general health, consumers are ... and, in some cases, reverse certain medical conditions, according to health and wellness research ... trying to manage a health or medical condition by making healthy food and beverage ...
(Date:8/12/2019)... (PRWEB) , ... August 12, 2019 , ... Eco ... Boulevard #315 in Pembroke Pines, Florida 33027. For over 25 years, Eco Pump Services ... and septic tank pumping services . Eco Pump’s steady five-star ratings and ...
(Date:8/12/2019)... (PRWEB) , ... August 12, 2019 , ... Parents craving ... not only nourish their families but also help feed children in need. IsaKids® Super ... Celebration 2019 event in Nashville, Tennessee. The global health and wellness company also debuted ...
Breaking Medicine News(10 mins):